Pharming Group N.V. ADR (PHAR) Stock Price, Quote & News

Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated pho...

Industry: Biotechnology

Sector: Healthcare

Phone: 31 71 524 7400

Website: www.pharming.com

Address:

Darwinweg 24, Leiden, Netherlands

De_Monitor Jul. 14 at 11:13 PM

$PHAR @PharmingIR Interesting wording, but this reads more like a corporate brochure than a clinical update. Patient recruitment is still ongoing, there are no efficacy data from the pivotal trial yet, and commercialization remains years away at best. Calling this a program with “clinical and regulatory visibility” is optimistic when the only real milestone investors should care about is whether the Phase III study actually succeeds. As with Orchard, potential is not the same as value creation. Investors will ultimately judge napazimone by trial results, not by polished descriptions of its market opportunity or Pharming’s infrastructure.

0 · Reply

PharmingIR Jul. 14 at 1:36 PM

$PHAR As Pharming advances patient recruitment in the FALCON study, napazimone (KL1333) reflects the strategic value of the Abliva acquisition and its role in expanding PHAR’s rare disease pipeline into mitochondrial DNA (mtDNA)-driven primary mitochondrial disease. The investigational late-stage program combines a novel mechanism of action, an ongoing pivotal study, FDA-agreed primary endpoints, and a positive interim analysis—features that provide important clinical and regulatory visibility at this stage. With more than 30,000 potentially addressable diagnosed mtDNA mitochondrial disease patients across the U.S., EU4, and the U.K., napizimone (KL1333) is being developed for a rare disease area with significant unmet medical need. Pharming has clinical development, regulatory, market access, and patient services infrastructure to support continued development and potential future commercialization of napazimone (KL1333) while leveraging its existing rare disease capabilities.

0 · Reply

PharmingIR Jul. 13 at 8:30 PM

$PHAR Pharming’s Joenja® (leniolisib) has received marketing authorization from the European Commission as the first approved treatment in the EU for activated phosphoinositide 3-kinase delta syndrome (APDS) in adult and pediatric patients aged 12 years and older—an important milestone in Pharming’s strategy to accelerate Joenja® expansion and broaden access for eligible patients with APDS. The initial launch is expected in Germany in Q3 2026, with additional EU countries to follow as national reimbursement negotiations progress. Supported by clinical data from the Phase II/III program, the EC authorization marks an important regulatory step for Joenja® in APDS across the EU. Collectively, these regulatory milestones reflect Pharming’s continued commitment to delivering innovative therapies that help transform the lives of people affected by rare disease communities globally.

0 · Reply

PharmingIR Jul. 13 at 2:45 PM

$PHAR Pharming continues to make strategic progress toward the potential U.S. pediatric expansion of Joenja® (leniolisib) for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS). The U.S. FDA’s recent acceptance of Pharming’s resubmitted supplemental New Drug Application (sNDA) seeking approval for 40 and 50 mg twice-daily dosing for this pediatric population represents an important regulatory milestone toward expanding Joenja®’s availability to younger patients. This regulatory step places the pediatric application on a defined U.S. regulatory review path, with an FDA decision by October 2026. Alongside recent progress in Europe and continued clinical development in immune dysregulation disorders, it supports the company’s strategy to broaden access to Joenja® and advance a focused rare immune and genetic disease pipeline. We will continue to share updates as part of Pharming’s ongoing commitment to advancing care.

0 · Reply

PharmingIR Jul. 9 at 2:35 PM

$PHAR For many investors, the long-term opportunity is tied not only to the success of Joenja® (leniolisib) in APDS, but also to how broadly the underlying science and Pharming’s high-value clinical pipeline develop and expand over time. RUCONEST® remains an important foundation and source of funding for the business, providing a source of durable revenues and cash flow that support PHAR’s continued investment in growth and pipeline development in broader primary immunodeficiencies and mitochondrial disease. While the HAE market has seen increased competition with new therapies focused on convenience and broader adoption, RUCONEST® continues to demonstrate resilience through its differentiated value proposition. It serves a specific and underserved segment of HAE patients with difficult-to-treat disease.

4 · Reply

PharmingIR Jul. 8 at 3:11 PM

$PHAR At the recent Jefferies Global Healthcare Conference in New York, Pharming’s leadership outlined a clear growth trajectory supported by its durable commercial foundation, the continued expansion of Joenja® (leniolisib), and an advancing clinical pipeline focused on rare immune and genetic disorders. Together, these priorities reflect Pharming’s balanced strategy: leveraging a durable commercial foundation while advancing development programs in rare immune and genetic disorders to support future growth and help improve the lives of people affected by rare diseases around the world. This approach continues to guide Pharming’s ambition to become a leading global rare disease company. You can find the full 2026 Jefferies Global Healthcare Conference Presentation here: https://www.pharming.com/investors/events-detail/jefferies-global-healthcare-conference-2026

1 · Reply

Ruconestor Jul. 7 at 8:49 PM

$PHAR There is a lot of news coming up.positive exciting researchresults

0 · Reply

PharmingIR Jul. 7 at 12:22 PM

$PHAR One important aspect of the Pharming story is that Joenja® (leniolisib) is being developed beyond its current approved indication for activated PI3Kδ syndrome (APDS). Pharming is actively investigating leniolisib across broader immune dysregulation disorders with significantly larger potential patient populations. At the same time, the company continues to expand its global APDS presence supported by recent regulatory progress in Europe and Japan, pediatric expansion efforts in the U.S., and ongoing international commercialization initiatives. What makes this progression particularly important is that for many patients these disorders share overlapping immune dysregulation features linked to PI3Kδ signaling, providing a strong scientific rationale to further study leniolisib across multiple indications. With additional studies already underway, 2026 could become an important year for generating further insight into leniolisib beyond APDS. Watch CEO Fabrice Chouraqui:

0 · Reply

Noobnr1 Jul. 7 at 5:16 AM

$OMER 🚀🌙💫 $PHAR 💎 $GILD 🥇$PFE slow growing 🤔

0 · Reply

PharmingIR Jul. 2 at 6:41 PM

$PHAR We are pleased to share that Joenja® (leniolisib) is now available in Germany for eligible patients with APDS aged 12 years and older, marking the first European launch following European Commission approval. This milestone was achieved as expected in Q3 2026, in line with the launch timeline communicated when EC approval was announced on May 22nd. Joenja® is the first approved treatment specifically for activated PI3Kδ syndrome (APDS) in Europe, and this launch represents an important step in expanding access for patients living with this rare primary immunodeficiency. Please find the May 22nd PR here: https://www.pharming.com/our-news/european-commission-grants-marketing-authorization-to-pharming-s-joenja-r-leniolisib-the-first

0 · Reply

Pharming Group Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 11:05 AM EDT - 5 weeks ago

Pharming Group Slides: FY 2026

Jun 4, 2026, 1:00 AM EDT - 5 weeks ago

Market Cap	972.51M
Revenue (ttm)	376.13M
Net Income (ttm)	2.85M
EPS (ttm)	N/A
PE Ratio	86.63
Forward PE	23.10
Profit Margin	0.76%
Debt to Equity Ratio	0.02

Volume	4,300
Avg Vol	11,006
Day's Range	N/A - N/A
Shares Out	70.63M
Stochastic %K	23%
Beta	-0.04
Analysts	Strong Sell
Price Target	$38.00